Industry news that matters to you.  Learn more

Archives for January 2011

Eisai Contracts with Proteome Sciences to Measure Candidate Alzheimer’s Biomarkers

Proteome Sciences has announced that it has been contracted by the Japanese pharmaceutical firm Eisai to provide biomarker services for Alzheimer’s disease.

MDxHealth Partners to Identify Predictive Biomarker for PARP Inhibition

MDxHealth has announced that they are partnering with Newcastle University in the UK, Cancer Research Technology and Pfizer to identify and develop biomarkers that can predict response to a PARP inhibitor.

GNS Healthcare Secures Contract to Unlock Mechanisms of Major Cancer Drugs with NCI 60 Data and REFS Data-driven Computational Models

GNS Healthcare, Inc. (GNS) announced that it has entered into a subcontract with SAIC-Frederick, Inc. in support of SAIC-Frederick’s prime contract with the National Cancer Institute. GNS will analyze National Cancer Institute (NCI) data generated from the application of several well-known cancer treatments to the NCI-60 cancer cell line panel. These drugs include several well-known, clinically active, mechanistically distinct anticancer agents: doxorubicin X2, Velcade® (bortezimib), paclitaxel, Sprycel® (dasatinib), Sutent® (sunitinib), and rapamycin. This collaboration will utilize GNS’s supercomputer-driven REFS™ platform to build computer models in a hypothesis-free, unbiased manner that will be simulated to identify key genetic and molecular mechanisms of drug efficacy and resistance in cancer. The goal of this project is to identify biomarkers and biological mechanisms that will lead to better matching of drugs to patients and new effective drugs in cancer. Financial terms of the agreement were not disclosed.

Spinal Muscular Atrophy Foundation and Rules-Based Medicine Collaborate on SMA Biomarker Panel

The Spinal Muscular Atrophy (SMA) Foundation and Rules-based Medicine (RBM) have reached the first milestone in a program to develop a panel of plasma protein biomarkers for SMA using RBM’s Multi-Analyte Profiling (MAP) technology platform.

Computable Genomix Secures Investment for the Development of Genetic Biomarker Tests

Memphis-based Computable Genomix announced this week that it has secured an investment from venture capital firm Innova Memphis to pilot a novel process for developing genetic biomarker tests. Leveraging its next-generation computational discovery capability, the company is developing highly targeted genetic biomarker tests for clinical researchers.